| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP2K5 |
| Uniprot No | Q13163 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-448aa |
| 活性数据 | MLWLALGPFP AMENQVLVIR IKIPNSGAVD WTVHSGPQLL FRDVLDVIGQ VLPEATTTAF EYEDEDGDRI TVRSDEEMKA MLSYYYSTVM EQQVNGQLIE PLQIFPRACK PPGERNIHGL KVNTRAGPSQ HSSPAVSDSL PSNSLKKSSA ELKKILANGQ MNEQDIRYRD TLGHGNGGTV YKAYHVPSGK ILAVKVILLD ITLELQKQIM SELEILYKCD SSYIIGFYGA FFVENRISIC TEFMDGGSLD VYRKMPEHVL GRIAVAVVKG LTYLWSLKIL HRDVKPSNML VNTRGQVKLC DFGVSTQLVN SIAKTYVGTN AYMAPERISG EQYGIHSDVW SLGISFMELA LGRFPYPQIQ KNQGSLMPLQ LLQCIVDEDS PVLPVGEFSE PFVHFITQCM RKQPKERPAP EELMGHPFIV QFNDGNAAVV SMWVCRALEE RRSQQGPP |
| 分子量 | 50.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MAP2K5蛋白的参考文献示例(注：以下内容为模拟文献，实际引用时请核实真实来源)：
---
1. **文献名称**: *Expression and Purification of Recombinant Human MAP2K5 in Escherichia coli*
**作者**: Zhang L, et al.
**摘要**: 该研究成功在大肠杆菌中表达并纯化了重组人MAP2K5蛋白，通过优化诱导条件和亲和层析技术获得了高纯度蛋白。酶活性分析表明，重组蛋白具有磷酸化下游靶点ERK5的能力，为激酶功能研究提供了工具。
---
2. **文献名称**: *Structural Insights into MAP2K5/MEK5 Activation Loop Dynamics*
**作者**: Thompson R, et al.
**摘要**: 利用重组人MAP2K5蛋白进行X射线晶体学研究，揭示了其激活环的构象变化对激酶活性的调控机制，并发现特定磷酸化位点对ERK5信号通路的激活至关重要。
---
3. **文献名称**: *MAP2K5-Mediated Signaling in Cardiac Hypertrophy*
**作者**: Suzuki K, et al.
**摘要**: 通过体外实验分析重组MAP2K5蛋白在心肌细胞中的功能，发现其通过激活ERK5通路参与病理性心脏肥大的发生，为靶向治疗提供了潜在方向。
---
4. **文献名称**: *High-Throughput Screening for MAP2K5 Inhibitors Using Recombinant Protein*
**作者**: Nguyen T, et al.
**摘要**: 利用重组MAP2K5蛋白建立体外激酶活性检测体系，筛选出小分子抑制剂，并验证其对癌症细胞增殖的抑制作用，表明MAP2K5作为治疗靶点的潜力。
---
以上示例综合了蛋白表达、结构功能、疾病机制及药物开发等研究方向，实际应用中建议通过学术数据库(如PubMed、Web of Science)检索最新文献。
Recombinant human MAP2K5 (Mitogen-Activated Protein Kinase Kinase 5), also known as MEK5. is a serine/threonine kinase that plays a pivotal role in the MAPK signaling pathway. As a dual-specificity kinase, it directly phosphorylates and activates the downstream mitogen-activated protein kinase ERK5 (MAPK7). The MAP2K5/ERK5 cascade is involved in regulating diverse cellular processes, including proliferation, differentiation, survival, and stress responses, particularly in endothelial cells, neurons, and cardiovascular tissues. Dysregulation of this pathway has been linked to cancers, inflammatory diseases, and cardiovascular disorders.
The recombinant form of MAP2K5 is typically produced in expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity for research applications. It lacks transmembrane domains but contains conserved catalytic and binding regions critical for interactions with ERK5 and upstream regulators like MAP3Ks (e.g., MEKK2/3). Researchers utilize recombinant MAP2K5 to study its activation mechanisms, screen kinase inhibitors, or model pathway disruptions in diseases. Its role in mediating both pro-survival and pro-apoptotic signals, depending on cellular context, makes it a target for therapeutic exploration in oncology and metabolic disorders. Structural studies of recombinant MAP2K5 also aid in designing selective drugs to minimize off-target effects in MAPK-related therapies.
×
